FENC Live signals | Maximize Profits with Getagraph.com

SELL 100426 min ago

@ $9.99

Issued: 14 Feb 2024 @ 09:33

Return: -7.51%

Previous signal: Feb 13 - 09:38

Previous signal: Buy

Return: -0.10 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	288 706
Average Volume	127 085
Market Cap	250.40M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.0400 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.40
ATR14	$0.0190 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Haigh Adrian	Sell	22 222	Option
2024-04-22	Haigh Adrian	Sell	22 223	Option
2024-04-22	Haigh Adrian	Buy	22 223	Common Shares
2024-04-19	Haigh Adrian	Buy	22 222	Common Shares
2024-04-22	Haigh Adrian	Sell	22 223	Common Shares

INSIDER POWER
4.44
Last 100 transactions
Buy: 1 387 411 \| Sell: 947 579

Volume Correlation

Long: -0.12 (neutral)

Short: 0.07 (neutral)

Signal:(50.795) Neutral

Fennec Pharmaceuticals Correlation

10 Most Positive Correlations
JD	0.927
NAKD	0.916
GBNH	0.912
WLTW	0.907
SIRI	0.906
LSXMA	0.906
LSXMK	0.906
DTSS	0.905
ALXO	0.904
GOOD	0.903

10 Most Negative Correlations
PAE	-0.924
GPACU	-0.915
CMLF	-0.909
LMNR	-0.909
PUCKU	-0.905
RAM	-0.905
GXII	-0.904
SGEN	-0.902
CSLMU	-0.9
EBSB	-0.896

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fennec Pharmaceuticals Correlation - Currency/Commodity

-0.16
( neutral )

-0.24
( neutral )

0.00
( neutral )

0.61
( weak )

-0.43
( neutral )

Fennec Pharmaceuticals Financials

Annual	2023
Revenue:	$21.64M
Gross Profit:	$20.36M (94.08 %)
EPS:	$-0.610

Q4	2023
Revenue:	$10.00M
Gross Profit:	$9.30M (92.96 %)
EPS:	$-0.100

Q3	2023
Revenue:	$6.52M
Gross Profit:	$6.18M (94.92 %)
EPS:	$-0.0702

Q2	2023
Revenue:	$3.33M
Gross Profit:	$3.18M (95.55 %)
EPS:	$-0.210

Financial Reports:

No articles found.

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.